EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study

Maria Arechederra, Emil Bik iD, Carla Rojo, Jasmin Elurbide iD, María Elizalde, Beata Kruk, Maciej Krasnodębski, Jan Pertkiewicz, Sławomir Kozieł, Michał Grąt, Joanna Raszeja-Wyszomirska, Maria Rullan und 14 weitere

Liver International · 2025

DOI: 10.1111/liv.70049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Maria Arechederra und 25 weiteren Autor:innen. Beteiligte Einrichtung: Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Cell-Free Nucleic Acids, Bile Duct Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon 2020 Framework Programme, Fundación Científica Asociación Española Contra el Cáncer, Thermo Fisher Scientific.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterised by inflammation and fibrosis of the bile ducts, conferring an increased risk of cholangiocarcinoma (CCA). However, detecting CCA early in PSC patients remains challenging due to the limited sensitivity of conventional diagnostic methods, including imaging or bile duct brush cytology during endoscopic retrograde cholangiopancreatography (ERCP). This study aims to evaluate the potential of bile cell‐free DNA (cfDNA) mutational analysis, termed the Bilemut assay, as a tool for CCA detection in PSC patients.

Methods

Sixty‐three PSC patients undergoing ERCP due to biliary strictures were prospectively recruited. Bile samples were collected, and cfDNA was extracted and analysed using the Oncomine Pan‐Cancer Cell‐Free assay. Twenty healthy liver donors were included for comparison. Samples with a mutant allele frequency (MAF) ≥ 0.1% were considered positive. Correlations between mutational status and clinical characteristics were assessed. Results cfDNA mutational analysis was successful in all bile samples. Mutations predominantly in KRAS , GNAS , and TP53 were detected in 36.5% (23/63) of PSC patients, compared to 10% (2/20) of healthy donors ( p = 0.0269). The clinical characteristics of Bilemut‐positive and ‐negative patients were comparable, though there was a trend towards a lower prevalence of inflammatory bowel disease in the Bilemut‐positive group. Among PSC patients diagnosed with CCA during follow‐up, 75% were Bilemut‐positive, suggesting an association between mutational status and malignancy risk.

Conclusions

Mutational analysis of cfDNA obtained from bile collected from PSC patients undergoing ERCP is feasible. Implementing the Bilemut assay may help identify patients needing closer surveillance and further imaging studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingCell-Free Nucleic AcidsBile Duct NeoplasmsCholangiocarcinomaBileHumansPilot ProjectsMaleFemaleMiddle AgedAdultProspective StudiesDNA Mutational AnalysisCholangiopancreatography, Endoscopic RetrogradeMutationAged

Stichwörter der Autor:innen

PSCbilecfDNAcholangiocarcinomacholangitischronic liver diseaseliquid biopsymutations

Substanzen

Cell-Free Nucleic Acids

Autor:innen und Institutionen

  • Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, Pamplona, Spain.
  • IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain.
  • Liver and Internal Medicine Unit, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Laboratory of Metabolic Liver Diseases, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Department of General Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.

ORCID-Profile: Emil Bik, Jasmin Elurbide, Pavel Strnad, Piotr Milkiewicz, Carmen Berasain

Förderung

  • Horizon 2020 Framework Programme
  • Fundación Científica Asociación Española Contra el Cáncer
  • Thermo Fisher Scientific
  • Euroregión Nueva Aquitania Euskadi Navarra
  • Departamento de Salud, Gobierno de Navarra
  • Dr. Rolf M. Schwiete Stiftung
  • Ministerio de Ciencia, Innovación y Universidades
  • Instituto de Salud Carlos III

Zitieren

APA

Arechederra, M., Bik, E., Rojo, C., Elurbide, J., Elizalde, M., Kruk, B., Krasnodębski, M., Pertkiewicz, J., Kozieł, S., Grąt, M., Raszeja-Wyszomirska, J., Rullan, M., Alkorta-Aranburu, G., Oyón, D., Fernández-Barrena, M. G., Candels, L. S., Białek, A., Krupa, Ł., Schneider, K. M., …, & Berasain, C. (2025). Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study. Liver International. https://doi.org/10.1111/liv.70049

Vancouver

Arechederra M, Bik E, Rojo C, Elurbide J, Elizalde M, Kruk B, et al. Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study. Liver International. 2025. doi:10.1111/liv.70049

BibTeX
@article{Arechederra2025,
  author = {Arechederra, Maria and Bik, Emil and Rojo, Carla and Elurbide, Jasmin and Elizalde, María and Kruk, Beata and Krasnodębski, Maciej and Pertkiewicz, Jan and Kozieł, Sławomir and Grąt, Michał and Raszeja-Wyszomirska, Joanna and Rullan, Maria and Alkorta-Aranburu, Gorka and Oyón, Daniel and Fernández-Barrena, Maite G and Candels, Lena S and Białek, Andrzej and Krupa, Łukasz and Schneider, Kai M and Urman, Jesús and Strnad, Pavel and Trautwein, Christian and Milkiewicz, Piotr and Krawczyk, Marcin and Ávila, Matías A and Berasain, Carmen},
  title = {Mutational Analysis of Bile Cell‐Free DNA in Primary Sclerosing Cholangitis: A Pilot Study},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70049}
}
Kostenlos starten →